All In Biotech

NDA 203565 · Am Regent

Injectafer

Ferric Carboxymaltose · Intravenous

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Jul 25, 2013

Approved uses

5

Original approval plus efficacy supplements

Registered trials

194

58 Phase 3, 13 recruiting

FAERS reports

4,728

2,512 serious, 90 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SYMPTOMATIC HYPOPHOSPHATEMIA • FERRIC CARBOXYMALTOSE INJECTION can cause severe, prolonged hypophosphatemia associated with serious outcomes, including hospitalization, osteomalacia and fractures requiring clinical intervention [see Warnings and Precautions ( 5 . 1 )]. • Hypophosphatemia has occurred in patients with normal baseline phosphate levels and without apparent risk factors for hypophosphatemia [see Warnings and Precautions ( 5.1 )]. • Check serum phosphate levels prior to a repeat course of treatment in patients at risk for low serum phosphate and in any patient who receives a repeat course of therapy within three months [see Dosage and Administration ( 2.1 , 2.3) ] . Correct pre-existing hypophosphatemia prior to administering FERRIC CARBOXYMALTOSE INJECTION [see Warnings and Precautions ( 5.1 )] . • Advise patients receiving FERRIC CARBOXYMALTOSE INJECTION about the...

What it is approved for

From the label in effect Sep 2, 2026.

Ferric carboxymaltose injection is indicated for the treatment of: • Iron deficiency anemia (IDA) in: adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. adult patients who have non-dialysis dependent chronic kidney disease. • Iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. Ferric carboxymaltose injection is an iron replacement product indicated for the treatment of: • iron deficiency anemia (IDA) in: adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. ( 1 ) adult patients who have non-dialysis dependent chronic kidney disease. ( 1 ) • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. ( 1 )

Mechanism: Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • INJECTAFER · FERRIC CARBOXYMALTOSE 750MG IRON/15ML (50MG IRON/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • INJECTAFER · FERRIC CARBOXYMALTOSE 100MG IRON/2ML (50MG IRON/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • INJECTAFER · FERRIC CARBOXYMALTOSE 500MG IRON/10ML (50MG IRON/ML) · SOLUTION, INTRAVENOUS · Prescription
  • INJECTAFER · FERRIC CARBOXYMALTOSE 1GM IRON/20ML (50MG IRON/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Ferric Carboxymaltose" as an intervention, any sponsor and status, largest first.

All 194 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypophosphataemia871
  • nausea553
  • pain430
  • dyspnoea399
  • headache370
  • product quality issue326
  • dizziness310
  • anxiety293
  • urticaria288
  • arthralgia280
  • emotional distress259
  • pruritus256

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20133
201445
2015170
2016205
2017395
2018473
2019656
2020525
2021578
2022628
2023352
2024252
2025257
2026189

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Injectafer (Ferric Carboxymaltose) · HCPCS J1439

2024 spending

$131M

Beneficiaries

73,218

147,578 claims

Per beneficiary

$1,793

2024 ASP limit $1.12 per unit

View as table
YearSpending
2020$149,785,035
2021$161,942,228
2022$155,020,670
2023$147,399,186
2024$131,249,161

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 227 on PubMed

Sponsor: Am Regent

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.